224 related articles for article (PubMed ID: 38685841)
61. New strategies for preventing graft-versus-host disease.
Murphy WJ; Blazar BR
Curr Opin Immunol; 1999 Oct; 11(5):509-15. PubMed ID: 10508701
[TBL] [Abstract][Full Text] [Related]
62. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease.
Thangavelu G; Du J; Paz KG; Loschi M; Zaiken MC; Flynn R; Taylor PA; Kirchmeier AK; Panoskaltsis-Mortari A; Luznik L; MacDonald KP; Hill GR; Maillard I; Munn DH; Serody JS; Murphy WJ; Miklos D; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Dahlberg C; Miller AT; Blazar BR
Blood; 2020 Jan; 135(1):28-40. PubMed ID: 31697815
[TBL] [Abstract][Full Text] [Related]
63. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
64. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
65. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
Front Immunol; 2021; 12():757836. PubMed ID: 34712243
[TBL] [Abstract][Full Text] [Related]
66. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
67. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation.
Murphy WJ; Longo DL
Immunol Rev; 1997 Jun; 157():167-76. PubMed ID: 9255629
[TBL] [Abstract][Full Text] [Related]
68. Mouse models of graft-versus-host disease: advances and limitations.
Schroeder MA; DiPersio JF
Dis Model Mech; 2011 May; 4(3):318-33. PubMed ID: 21558065
[TBL] [Abstract][Full Text] [Related]
69. Preclinical Studies of MSC-Derived Extracellular Vesicles to Treat or Prevent Graft Versus Host Disease: a Systematic Review of the Literature.
Gupta M; Tieu A; Slobodian M; Shorr R; Burger D; Lalu MM; Allan DS
Stem Cell Rev Rep; 2021 Apr; 17(2):332-340. PubMed ID: 33159616
[TBL] [Abstract][Full Text] [Related]
70. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
71. Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect.
Janikashvili N; Gérard C; Thébault M; Brazdova A; Boibessot C; Cladière C; Ciudad M; Greigert H; Ouandji S; Ghesquière T; Samson M; Audia S; Saas P; Bonnotte B
Oncoimmunology; 2021 Feb; 10(1):1880046. PubMed ID: 33659098
[TBL] [Abstract][Full Text] [Related]
72. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
73. A Canine Model of Chronic Graft-versus-Host Disease.
Graves SS; Rezvani A; Sale G; Stone D; Parker M; Rosinski S; Spector M; Swearingen B; Kean L; Storb R
Biol Blood Marrow Transplant; 2017 Mar; 23(3):420-427. PubMed ID: 28013013
[TBL] [Abstract][Full Text] [Related]
74. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).
Taylor PA; Ehrhardt MJ; Lees CJ; Tolar J; Weigel BJ; Panoskaltsis-Mortari A; Serody JS; Brinkmann V; Blazar BR
Blood; 2007 Nov; 110(9):3480-8. PubMed ID: 17606761
[TBL] [Abstract][Full Text] [Related]
75. Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice.
Buchele V; Büttner-Herold M; Vogler T; Neurath MF; Hildner K
J Vis Exp; 2019 Feb; (144):. PubMed ID: 30799849
[TBL] [Abstract][Full Text] [Related]
76. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
Sato M; Storb R; Loretz C; Stone D; Mielcarek M; Sale GE; Rezvani AR; Graves SS
Transplantation; 2013 Jul; 96(1):34-41. PubMed ID: 23694952
[TBL] [Abstract][Full Text] [Related]
77. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
Schorlemmer HU; Kurrle R; Bartlett RR
Drugs Exp Clin Res; 1997; 23(5-6):167-73. PubMed ID: 9515226
[TBL] [Abstract][Full Text] [Related]
78. Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease.
Kilgour JM; Wali G; Gibbons E; Scherwath A; Barata Badiella A; Peniket A; Schoemans H; Matin RN;
Biol Blood Marrow Transplant; 2020 May; 26(5):e113-e127. PubMed ID: 32028026
[TBL] [Abstract][Full Text] [Related]
79. Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation.
Fujiwara H
Front Immunol; 2021; 12():703298. PubMed ID: 34512627
[TBL] [Abstract][Full Text] [Related]
80. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
